US · QLGN
Qualigen Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Carlsbad, CA 92011
- Website
- qlgntx.com
Price · as of 2024-12-31
—
Market cap 4.45M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $1,247.75 | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $6.29 | $69.48 | |||
| 2019 | |||||
| 2020 | $1,665.00 | $3.36 | $0.00 | $132.02 | |
| 2021 | $300.00 | $162.08 | $0.00 | $0.00 | $0.00 |
| 2022 | $54.00 | $45.01 | $0.00 | $0.00 | $17.30 |
| 2023 | $20.25 | $61.71 | $0.00 | $0.00 | $0.00 |
| 2024 | $3.12 | $1,247.75 |
AI valuation
Our deep-learning model estimates Qualigen Therapeutics, Inc.'s (QLGN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $1,247.75
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| QLGN | Qualigen Therapeutics, In… | $2.63 | 4.45M | +47,343% | — | — | — | -0.18 | 0.42 | — | 0.01 | -0.03 | 0.42 | 0.00% | — | — | -2210.05% | -3863.24% | -189.27% | 0.00 | -6.34 | 2.33 | 1.59 | 0.22 | 60244.00% | -10000.00% | -3859.00% | -560.87% | -3.15 | -4242.60% | 7.77% | -1.40% | 191.43% | 0.01 | 0.01 | — | -39.80 |
| CMND | Clearmind Medicine Inc. | $0.79 | 4.3M | — | — | — | — | -0.08 | 0.25 | — | 0.94 | — | 0.27 | 0.00% | — | — | -180.28% | 180.16% | -58.05% | 1.49 | -290.07 | 1.22 | 1.21 | 0.58 | -5494.00% | — | -189.00% | -1590.11% | -0.97 | 150.51% | 0.00% | 0.00% | 0.00% | 0.62 | 0.74 | — | -9.25 |
| CNSP | CNS Pharmaceuticals, Inc. | $6.82 | 3.92M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| ENSC | Ensysce Biosciences, Inc. | $2.08 | 4.93M | +770,652,285% | -3% | — | — | -1.10 | 2.36 | 1.68 | -0.83 | — | 2.36 | -38.57% | -129.17% | -153.30% | -471.83% | 16069.72% | -192.33% | 0.08 | -5.22 | 2.42 | 1.64 | 0.48 | -256.00% | 13353.00% | 6959834645.00% | -85550186.53% | -3399198.17 | 17914756446.99% | 3306.75% | -3630.90% | 3340.18% | -0.83 | 0.00 | 1.07 | -32.39 |
| KALA | KALA BIO, Inc. | $0.76 | 5.35M | — | — | — | — | -1.01 | 3.16 | — | -0.49 | — | 3.16 | 0.00% | — | — | -388.29% | 599.82% | -69.12% | 2.62 | -7.09 | 3.11 | 3.02 | 0.46 | -5977.00% | — | 369.00% | -76.03% | -1.73 | 433.08% | 0.00% | 0.00% | 11.20% | -0.49 | -0.68 | — | -17.97 |
| KZIA | Kazia Therapeutics Limite… | $7.68 | 4.42M | +110% | -60% | — | +13,728% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| SNGX | Soligenix, Inc. | $1.38 | 4.5M | — | — | — | — | -0.48 | 0.96 | — | 0.25 | — | 0.96 | 0.00% | — | — | -248.97% | 387.20% | -88.11% | 0.36 | — | 1.82 | 1.61 | 0.67 | -6066.00% | — | -233.00% | -213.60% | -1.73 | 361.77% | 0.00% | 0.00% | 35.16% | 0.25 | 0.29 | — | -38.99 |
| XBIO | Xenetic Biosciences, Inc. | $2.77 | 4.27M | +9,985% | -13% | — | — | -1.47 | 0.97 | 2.32 | 0.09 | — | 0.97 | 100.00% | -168.16% | -158.39% | -50.12% | -1285.35% | -45.24% | 0.00 | — | 7.37 | 6.89 | 1.52 | -517.00% | -156.00% | -3152.00% | -48.55% | -3.15 | -861.34% | 0.00% | 0.00% | 0.00% | 0.09 | 0.13 | -0.14 | -36.77 |
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
- CEO
- Kevin A. Richardson II
- Employees
- 4
- Beta
- 0.28
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).